Abstract
Abstract : The immunomodulatory drug FK-506 (Tacrolimus) is a calcineurin inhibitor that, as such, indirectly inhibits the transcription of a gene encoding interleukin 2, a cytokine that is vital to the immune response process. Since its introduction in 1987, sporadic reports have appeared describing the development of thrombotic thrombocytopenic purpura (TTP) - or a similar syndrome - in patients taking this drug. Sirolimus (Rapamune) is another immunomodulatory drug with a more favorable side-effects profile than calcineurin inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
